Skip to Main Content

Antibody

Animal-origin-free proteins for every step of Antibody manufacturing.

From clone selection to sterile fill, recombinant albumin, transferrin, lactoferrin, and insulin supplements replace serum and serum albumin in CHO culture and stabilize the finished antibody.

Where InVitria proteins fit in Antibody Manufacturing

Monoclonal antibody production relies on albumin, transferrin, and insulin to grow CHO clones and seed trains, and on albumin again to protect the antibody downstream. Serum and serum albumin, bovine or human, bring lot-to-lot variability into culture. Defined, animal-origin-free proteins replace them in culture, then limit adsorptive loss through purification and stabilize the antibody through formulation and fill.

Where our products fit

The Antibody workflow, step by step.

Select a step to see where InVitria products fit.

Cell Line/Clone Selection

Identify and stabilize a high-titer, high-quality CHO clone under selection pressure while removing serum and undefined animal components from cloning media.

Overview

Cell line and clone selection identifies the CHO-derived clone that will manufacture the monoclonal antibody, screening for specific productivity, growth rate, genetic stability, and product quality attributes such as glycosylation and charge variant profile.

Selection is typically run under drug or nutrient selection pressure at low seeding density, where individual clones have minimal paracrine support and are vulnerable to nutrient and redox stress. Serum and other undefined animal-derived components introduce media lot variability that complicates clone ranking.

Defined, animal-origin-free selection media supports consistent clone screening and generates productivity and quality data that transfers reliably into scale-up and cell banking.

Functions

Selection Media Support

At the low seeding densities used in limiting-dilution and single-cell cloning, individual clones have minimal paracrine support and are vulnerable to nutrient, lipid, and redox stress. Carrier proteins in the media bind free fatty acids, hormones, and trace metals and buffer oxidative stress, improving clonal outgrowth and survival during selection.

Recommendation
Cellastim® S

Cell culture recombinant albumin to enhance proliferation in serum free and chemically defined cell culture. Lyophilized.

Commonly replaces
Serum albumin (HSA/BSA) in selection media.

Seed Train & Inoculum Expansion

Sustain rapid, viable seed-train growth and consistent inoculum quality across passages while replacing serum-derived growth and iron-transport components with defined recombinant proteins.

Overview

Seed train expansion carries the CHO working cell bank through successive passages to generate enough viable, actively growing cells to inoculate the production bioreactor at target seeding density, with doubling time and viability held consistent at each passage.

Expansion performance depends on nutrient and iron availability, protection from oxidative and shear stress during repeated passaging, and freedom from undefined animal-derived components that vary lot to lot and can obscure early process drift. Iron delivery and growth-factor signaling are especially sensitive during this scale-up phase.

A defined, animal-origin-free seed-train strategy supports reproducible passage-to-passage growth kinetics and delivers a consistent, on-spec inoculum to the production bioreactor.

Functions

Cell Expansion Support

Serum-free CHO expansion requires exogenous replacement of the growth-supporting activities normally supplied by serum: insulin signaling for glucose uptake and biosynthesis, iron transport, a lipid-carrier and antioxidant protein, and redox buffering. Loss of any one of these activities slows doubling time or increases passage-to-passage variability during seed-train scale-up.

Recommendation
ITSE+A Animal-Free®

Five-component 100x supplement of recombinant insulin, recombinant human transferrin, selenium, ethanolamine, and recombinant human albumin for serum-free cell culture.

Commonly replaces
FBS or animal serum supplementation

Iron Transport

Iron supports ribonucleotide reductase activity, mitochondrial respiration, and heme-dependent enzymes needed for rapid CHO proliferation. Supplementing iron as free ferrous or ferric salts generates hydroxyl radicals via Fenton chemistry that damage membranes and DNA; protein-bound delivery through the transferrin receptor avoids this oxidative burden.

Recommendation
Optiferrin®

Recombinant human transferrin, lyophilized, for iron delivery in serum-free and chemically defined media.

Growth & Apoptosis Protection

Passaging stress, shear during pipetting and pumping, and nutrient shifts between passages can trigger apoptotic signaling in expanding CHO cultures. Growth-factor pathways signaling through IGF-like receptors support proliferation and suppress apoptosis, while reducing reactive oxygen species helps preserve viability across passages.

Recommendation
Lacromin®

Recombinant human holo-lactoferrin, an iron-saturated lyophilized powder for serum-free and chemically defined cell culture media.

Production Bioreactor (Fed-Batch)

Sustain high viable cell density and volumetric titer in sparged fed-batch culture while replacing Poloxamer 188 with a shear protectant shown to raise titer.

Overview

The production bioreactor cultures CHO cells at scale in fed-batch mode, with continuous sparging and agitation to maintain dissolved oxygen and mixing while concentrated feed additions extend the production phase and support high final titer.

Sparging and impeller agitation generate hydrodynamic shear and bubble-associated interfacial stress that can damage cell membranes, particularly at the agitation and aeration rates required for high-density fed-batch culture. Poloxamer 188 (Pluronic F-68), the standard shear protectant, has been tied to documented lot-to-lot quality issues linked to high-molecular-weight polypropylene-oxide impurities.

Replacing Poloxamer 188 with a recombinant albumin-based shear protectant removes this impurity risk while directly supporting integrated viable cell count and titer through the fed-batch run.

Functions

Shear Protection & Titer Support

Sparging and agitation in stirred-tank bioreactors expose CHO cells to hydrodynamic shear and bubble rupture at the gas-liquid interface, both of which can compromise membrane integrity at the aeration and agitation rates required for high-density fed-batch culture. Surface-active shear protectants coat cell membranes and stabilize bubble interfaces to reduce this damage.

Recommendation
Cellastim® S

Cell culture recombinant albumin to enhance proliferation in serum free and chemically defined cell culture. Lyophilized.

Commonly replaces
Serum albumin (HSA/BSA) and serum in production media.

Harvest & Clarification

Remove cells and particulates from harvest fluid while preventing non-specific antibody loss to filter and hardware surfaces during clarification.

Overview

Harvest and clarification separates the secreted monoclonal antibody from cells, cell debris, and other insoluble material at the end of the fed-batch run, typically using centrifugation followed by depth and membrane filtration.

Dilute antibody streams are prone to non-specific adsorption onto filter membranes, tubing, and other process-contact surfaces, particularly at lower protein concentration or higher relative surface area. This adsorptive loss reduces recovered yield and varies with surface area, flow rate, and hold time.

Including a defined carrier protein in the harvest fluid saturates available binding surfaces and protects the antibody from adsorptive loss without introducing animal-derived material into the clarified pool.

Functions

Anti-Adsorption

Dilute protein solutions in contact with high surface-area materials such as depth filters, membrane filters, and tubing are susceptible to non-specific adsorption, measurably reducing recovered product, especially at low in-process concentration. Bulk carrier proteins compete for these binding sites and limit target-protein loss.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Protein A Capture Chromatography

Maximize antibody recovery through Protein A capture while limiting non-specific loss to resin and hardware and protecting product through low-pH elution.

Overview

Protein A capture chromatography uses immobilized Staphylococcal Protein A to selectively bind the Fc region of the antibody from clarified harvest fluid, concentrating it into a small eluate volume and removing most host cell protein and DNA in a single step.

In-process antibody concentration during load is dilute relative to final drug substance, and the low-pH conditions used to elute bound antibody from Protein A resin can promote aggregation for antibodies with limited conformational stability at low pH. Non-specific adsorption to resin, frits, and hardware adds further, difficult-to-trace yield loss.

A defined carrier protein added at low concentration in load or elution buffers reduces surface-mediated loss without interfering with Fc-Protein A binding chemistry.

Functions

Anti-Adsorption

Dilute in-process antibody streams passing through Protein A resin beds, frits, and chromatography hardware are susceptible to non-specific adsorptive loss at each contact surface, and low-pH elution conditions can additionally promote transient aggregation. Bulk carrier protein included in load, wash, or elution buffers competes for non-specific binding sites, reducing cumulative yield loss across the step.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Viral Inactivation

Achieve validated viral clearance through low-pH or solvent/detergent treatment of Protein A eluate ahead of polishing chromatography.

Overview

Viral inactivation treats the Protein A eluate to inactivate enveloped viral contaminants before further purification, most commonly by low-pH hold or solvent/detergent treatment, as part of the platform’s overall viral clearance strategy.

Low-pH inactivation holds the eluate at pH 3.5 to 3.8 for a validated hold time, denaturing the lipid envelope and associated proteins of enveloped viruses; solvent/detergent treatment disrupts the envelope directly. Both mechanisms act on virus structure, though low pH must be controlled to limit antibody aggregation.

This step is a chemical treatment rather than a media or buffer touchpoint, so it does not use a stabilizing carrier protein excipient; process control instead focuses on pH, hold time, and temperature to achieve validated log-reduction values while preserving antibody quality.

Polishing Chromatography

Achieve final purity specifications by removing residual host cell protein, DNA, aggregates, and leached Protein A while limiting antibody loss to resin and hardware.

Overview

Polishing chromatography follows viral inactivation and uses one or more orthogonal separation mechanisms, typically anion exchange and cation exchange or hydrophobic interaction, to remove residual host cell protein, DNA, aggregated antibody, and leached Protein A ligand to meet final drug substance purity specifications.

Because polishing steps run at lower protein concentration and higher purity requirements than capture, non-specific adsorption to resin and hardware surfaces represents a proportionally larger share of total yield loss and can alter impurity clearance profiles run to run.

Including a defined carrier protein in polishing buffers limits this surface-mediated antibody loss while remaining orthogonal to the resin’s separation chemistry.

Functions

Anti-Adsorption

Polishing steps operate at the protein concentrations and surface exposure where non-specific adsorptive loss is proportionally most significant, since the antibody has already been concentrated but must still traverse resin beds, frits, and hardware before reaching final purity. Carrier protein competes for available binding surfaces to limit this loss.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Viral Filtration

Achieve robust, validated viral clearance by size-exclusion retention through a nanofiltration membrane downstream of polishing chromatography.

Overview

Viral filtration passes the polished antibody pool through a nanofiltration membrane with a defined pore-size rating, typically around 20 nanometers, that retains virus particles by size exclusion while allowing the smaller antibody molecule to pass through.

Clearance depends on membrane pore-size distribution, transmembrane pressure, and antibody concentration; because retention is a physical mechanism rather than a chemical or biological interaction, it provides viral clearance orthogonal to and independent of the earlier inactivation step.

This step is a physical membrane-retention operation rather than a media or buffer touchpoint, so it does not use a stabilizing carrier protein excipient; process control focuses on membrane integrity testing, flux, and pressure to confirm validated viral clearance without product loss.

UF/DF & Formulation

Concentrate purified antibody and exchange into formulation buffer via ultrafiltration/diafiltration while protecting against aggregation and surface-driven loss.

Overview

UF/DF and formulation uses ultrafiltration/diafiltration to raise purified antibody to target concentration, often 50 to 150 mg/mL for subcutaneous products, and exchange it into the final formulation buffer, removing residual process buffer components.

High-concentration UF/DF exposes antibody to elevated local concentration at the membrane surface, shear from recirculation pumps, and extended processing time, conditions that favor aggregation and viscosity-related processing challenges, particularly for antibodies with limited colloidal stability at high concentration. Undefined stabilizers introduce variability difficult to distinguish from genuine process instability.

A defined stabilizing protein added during or after UF/DF protects native antibody conformation through concentration and diafiltration without adding undefined animal-derived material to the formulation buffer.

Functions

Formulation Stabilization

Membrane concentration exposes antibody to elevated local concentration at the membrane wall, shear from recirculation, and extended processing time, all of which can promote aggregation or denaturation, particularly at the high concentrations used for subcutaneous formulations. Stabilizing proteins reduce surface- and concentration-driven unfolding during UF/DF.

Recommendation
Optibumin® 25

Approved excipient 25% recombinant human serum albumin, supplied in bottles and closed-system friendly bags for processing, formulation, cryopreservation, and advanced biomanufacturing.

Sterile Fill & Finish

Protect antibody from interfacial stress during aseptic filling using a recombinant albumin excipient with clinical precedent in an approved injectable product.

Overview

Sterile fill and finish aseptically fills the formulated antibody drug product into vials, syringes, or cartridges under sterile conditions, completing manufacturing ahead of labeling and distribution.

Filling operations expose antibody to air-liquid interfacial stress, agitation and shear during pumping and needle transit, and adsorption to container and stopper surfaces, all of which can drive subvisible particle formation and aggregation, particularly for high-concentration formulations processed at filling-line speeds.

Recombinant human albumin has regulatory precedent as an injectable formulation excipient: it is the stabilizing excipient, at 0.25% concentration, in Merck’s ERVEBO, the first rice-derived recombinant HSA approved as a novel excipient in an FDA/EMA/PMDA-approved human injectable product.

Functions

Formulation Excipient

Aseptic filling exposes antibody to air-liquid interfacial stress, agitation and shear during pumping and needle transit, and adsorption to container and stopper surfaces, conditions that can drive subvisible particle formation and aggregation, particularly at filling-line speeds and high formulation concentration. Stabilizing excipients occupy interfacial and container surfaces and limit interfacial unfolding.

Recommendation
Exbumin®

Approved excipient recombinant human serum albumin, supplied as a lyophilized powder for therapeutic formulation, vaccine stabilization, and viral vector processing.